<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stasis dermatitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stasis dermatitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Stasis dermatitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony F Fransway, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H358752"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Stasis dermatitis, or stasis eczema, is a common, inflammatory dermatosis of the lower extremities occurring in patients with chronic venous insufficiency, often in association with varicose veins, dependent chronic edema, hyperpigmentation, lipodermatosclerosis, and ulcerations  (<a class="graphic graphic_picture graphicRef70596 graphicRef78163" href="/z/d/graphic/70596.html" rel="external">picture 1A-B</a>). Stasis dermatitis may rarely involve the upper limbs in patients with artificial arteriovenous fistulas for hemodialysis or congenital arteriovenous malformations [<a href="#rid1">1,2</a>].</p><p>This topic will discuss the pathogenesis, clinical presentation, complications, and treatment of stasis dermatitis. The pathophysiology, clinical and diagnostic evaluation, differential diagnosis, and treatment of lower extremity chronic venous disease are discussed separately. The management of lower extremity venous ulcers is also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8202.html" rel="external">"Pathophysiology of chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8198.html" rel="external">"Clinical manifestations of lower extremity chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8196.html" rel="external">"Diagnostic evaluation of lower extremity chronic venous disease"</a>.)</p><p></p><p class="headingAnchor" id="H214055"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Prevalence estimates of chronic venous insufficiency vary from 1 to 40 percent in females and 1 to 17 percent in males [<a href="#rid3">3</a>]. In a Turkish study, stasis dermatitis was reported in 6.2 percent of hospitalized patients over the age of 65 [<a href="#rid4">4</a>].</p><p>Established risk factors for varicose veins and chronic venous insufficiency include age, family history of venous disease, female sex, standing occupation, obesity, and history of deep vein thrombosis [<a href="#rid3">3,5</a>]. Heart failure and hypertension are aggravating factors. (See  <a class="medical medical_review" href="/z/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease", section on 'Epidemiology and risk factors'</a>.)</p><p class="headingAnchor" id="H26659689"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Stasis dermatitis is caused by venous hypertension, which in most cases results from dysfunction of the venous valves, obstruction to the venous flow, or failure of the calf muscle "venous pump" [<a href="#rid6">6,7</a>]. If the valves of deep or perforator veins are incompetent, the increased pressure generated during standing or calf muscle contraction causes blood to reflux into the superficial venous system, converting it into a high-pressure system. (See  <a class="medical medical_review" href="/z/d/html/8202.html" rel="external">"Pathophysiology of chronic venous disease", section on 'Genesis and consequences of chronic venous hypertension'</a>.)</p><p>Venous hypertension induces microcirculatory changes in the dermis, including dilated capillaries and increased permeability that lead to pericapillary fibrin cuffs and edema, leucocyte accumulation and adhesion to vascular endothelium, hemosiderin deposits, and hyperplastic venules. Ultrastructural and immunohistochemical studies of biopsies of skin affected by stasis dermatitis have shown thickening of basal lamina of capillaries; elevated numbers of macrophages, T lymphocytes, and mast cells; and upregulation of matrix metalloproteinases [<a href="#rid6">6,8,9</a>]. These findings support the hypothesis that chronic inflammation induced by venous hypertension is central in the pathogenesis of stasis dermatitis.</p><p class="headingAnchor" id="H310245"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Stasis dermatitis is a late manifestation of chronic venous disease (stage C4 of the Clinical-Etiology-Anatomy-Pathophysiology [CEAP] classification  (<a class="graphic graphic_table graphicRef52388" href="/z/d/graphic/52388.html" rel="external">table 1</a>)) [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/z/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'CEAP classification'</a>). It typically presents with erythematous, scaling, and eczematous patches or plaques on chronically edematous legs [<a href="#rid2">2</a>]. The medial ankle is most frequently and severely involved, although the skin changes may extend up to the knee and down to the foot  (<a class="graphic graphic_picture graphicRef70596 graphicRef50640 graphicRef78163 graphicRef72689 graphicRef64878" href="/z/d/graphic/70596.html" rel="external">picture 1A-E</a>). Pruritus is variable but, when present, results in lichenification from chronic scratching or rubbing.</p><p>Acute stasis dermatitis may present with severely inflamed, weeping plaques; vesiculation; and crusting. Impetiginized crusts and/or pustules due to bacterial or candidal superinfection may also be seen. Acute stasis dermatitis and acute flares on a background of chronic dermatitis are often misdiagnosed as cellulitis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Hyperpigmentation due to dermal hemosiderin deposition and scaling are predominant features in chronic forms. Other signs of chronic venous insufficiency and related comorbidities are often present, including (see  <a class="medical medical_review" href="/z/d/html/8198.html" rel="external">"Clinical manifestations of lower extremity chronic venous disease"</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Varicose veins</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary lymphedema</p><p class="bulletIndent1"><span class="glyph">●</span>Atrophie blanche (stellate, porcelain-white scarring areas resulting from microthromboses)  (<a class="graphic graphic_picture graphicRef87627" href="/z/d/graphic/87627.html" rel="external">picture 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Lipodermatosclerosis </p><p class="bulletIndent1"><span class="glyph">●</span>Ulceration </p><p></p><p class="headingAnchor" id="H1690021628"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Hyperkeratosis, parakeratosis, acanthosis, and mild spongiosis are the epidermal changes usually seen in uncomplicated stasis dermatitis. Spongiosis may be prominent in cases with a superimposed contact dermatitis. Dermal changes include proliferation of small blood vessels in the papillary dermis; variable dermal fibrosis; perivascular, lymphocytic infiltration; extravasated erythrocytes; and hemosiderin-laden macrophages [<a href="#rid11">11</a>]. A positive iron stain and the evaluation of the iron deposition pattern may be helpful to confirm the diagnosis [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H310424"><span class="h1">COMPLICATIONS</span></p><p class="headingAnchor" id="H107526"><span class="h2">Contact sensitization</span><span class="headingEndMark"> — </span>Patients with stasis dermatitis and venous leg ulcers have a higher frequency of contact allergy than the general population. In a retrospective study of patients with stasis dermatitis referred for patch testing, 47 percent had a concurrent diagnosis of allergic contact dermatitis [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/13653.html" rel="external">"Basic mechanisms and pathophysiology of allergic contact dermatitis"</a>.)</p><p>Superimposed allergic contact dermatitis may present as an acute dermatitis characterized by vesiculation, localized weeping, and the development or worsening of pruritus. It may also be relatively occult and diagnosed only with a high index of suspicion, meticulous history of exposures, and epicutaneous patch testing. (See <a class="local">'Patch testing'</a> below.)</p><p>Polysensitization is common. A multicenter study of 423 patients with leg ulcers found an average of four positive patch tests per patient [<a href="#rid14">14</a>]. The number of sensitivities increased with the disease duration.</p><p>The susceptibility to contact dermatitis in patients with stasis dermatitis and leg ulcers may be due to several factors, including [<a href="#rid15">15-17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged and repeated contact with topical preparations containing strong sensitizers</p><p class="bulletIndent1"><span class="glyph">●</span>Local hypervascularization</p><p class="bulletIndent1"><span class="glyph">●</span>Increased number of lymphocytes and Langerhans cells in the affected skin</p><p class="bulletIndent1"><span class="glyph">●</span>Impairment of the skin barrier function</p><p></p><p>The substances most frequently responsible for contact sensitization among patients with stasis dermatitis and/or leg ulcers are ingredients of many emollients, topical prescriptions, and over-the-counter preparations, including [<a href="#rid13">13,14</a>] (see  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Fragrance mix</p><p class="bulletIndent1"><span class="glyph">●</span><em>Myroxylon pereirae</em> (formerly called balsam of Peru)</p><p class="bulletIndent1"><span class="glyph">●</span>Topical antibiotics (eg, <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a>, <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">bacitracin</a>, and aminoglycosides)</p><p class="bulletIndent1"><span class="glyph">●</span>Antiseptics (eg, povidone-iodine, benzalkonium chloride, <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Preservatives (quaternium-15, diazolidinyl urea)</p><p class="bulletIndent1"><span class="glyph">●</span>Rubber and constituents of rubber, rubber accelerators, and latex products</p><p class="bulletIndent1"><span class="glyph">●</span>Bandages, dressings, or adhesives (eg, colophony, epoxy resin, and formaldehyde resin)</p><p class="bulletIndent1"><span class="glyph">●</span>Topical corticosteroids (a list of cross-reacting topical corticosteroids is provided  (<a class="graphic graphic_figure graphicRef63402" href="/z/d/graphic/63402.html" rel="external">figure 1</a>))</p><p></p><p class="headingAnchor" id="H59262247"><span class="h2">Autosensitization (autoeczematization)</span><span class="headingEndMark"> — </span>Autosensitization (autoeczematization or "id" reaction) refers to an acute, pruritic, papulovesicular eruption that develops at cutaneous sites distant from a primary focus and is unrelated to the inciting cause of the primary inflammation [<a href="#rid18">18</a>]. Autosensitization has been reported in association with stasis dermatitis, contact dermatitis, and bacterial or fungal infections [<a href="#rid19">19,20</a>]. Typically, the autoeczematization develops one to two weeks after the primary inflammation and most frequently involves the forearms, thighs, trunk, and face [<a href="#rid18">18</a>].</p><p>The pathogenesis is not fully understood. Histologic findings are nonspecific and include spongiosis and a dermal, lymphohistiocytic infiltrate with eosinophils. Autosensitization due to stasis dermatitis may require treatment with topical and systemic corticosteroids.</p><p class="headingAnchor" id="H523344193"><span class="h2">Superinfection</span><span class="headingEndMark"> — </span>In patients with acute stasis dermatitis, moist, exudative lesions are often extensively colonized by bacteria and fungi. The disruption of the epidermal barrier integrity by inflammation or scratching favors the secondary infection of eczematous lesions. <em>Staphylococcus aureus</em> and <em>Streptococcus pyogenes </em>are the most frequent causes of superficial (impetiginization) or deep (cellulitis and erysipelas) superinfection of stasis dermatitis [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo"</a> and  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2820216835"><span class="h2">Lipodermatosclerosis</span><span class="headingEndMark"> — </span>Lipodermatosclerosis is a chronic form of panniculitis resulting from chronic inflammation, fat degeneration, and fibrosis. In the acute phase, lipodermatosclerosis presents with a painful erythema of the medial perimalleolar region that mimics cellulitis [<a href="#rid21">21</a>]. In contrast with cellulitis, lipodermatosclerosis develops slowly (over weeks to months) and usually involves both legs. The chronic phase is characterized by hyperpigmented and indurated skin that constricts the ankle region, giving the legs an appearance of an inverted champagne bottle  (<a class="graphic graphic_picture graphicRef65447" href="/z/d/graphic/65447.html" rel="external">picture 3</a>). Histopathology shows septal involvement of the subcutaneous fat, fat necrosis, microcyst formation, lipomembranous changes, elastosis, and calcification of adipocytes [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/8198.html" rel="external">"Clinical manifestations of lower extremity chronic venous disease", section on 'Lipodermatosclerosis (C4b)'</a>.)</p><p class="headingAnchor" id="H3167577877"><span class="h2">Acroangiodermatitis</span><span class="headingEndMark"> — </span>Acroangiodermatitis, also called "pseudo-Kaposi sarcoma," is a rare, reactive, vasoproliferative disorder resembling Kaposi sarcoma that occurs on the lower limbs as a result of vascular hyperplasia secondary to hypostasis and elevated venous pressure [<a href="#rid24">24,25</a>]. It presents with purpuric macules and papules that may coalesce and form large, purple-brown plaques on the extensor surfaces of the legs and dorsa of the feet  (<a class="graphic graphic_picture graphicRef118086 graphicRef118087" href="/z/d/graphic/118086.html" rel="external">picture 4A-B</a>).</p><p>Acroangiodermatitis can mimic and complicate stasis dermatitis. Histologically, the lesions consist of a proliferation of small, dilated dermal capillaries lined by plump endothelial cells with minimal or no atypia that are positive for CD31 and CD34 but, in contrast with true Kaposi sarcoma, negative for human herpesvirus (HHV) 8 [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/7726.html" rel="external">"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis"</a>.)</p><p class="headingAnchor" id="H26659798"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3668267841"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>The diagnosis of stasis dermatitis is usually clinical, based on:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical appearance of the skin lesions  (<a class="graphic graphic_picture graphicRef70596 graphicRef50640 graphicRef56758" href="/z/d/graphic/70596.html" rel="external">picture 1A, 1C, 1F</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of venous insufficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of other signs of chronic venous insufficiency (eg, varicose veins, pitting edema, hyperpigmentation  (<a class="graphic graphic_figure graphicRef139796" href="/z/d/graphic/139796.html" rel="external">figure 2</a>))</p><p></p><p class="headingAnchor" id="H1969472672"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>A skin biopsy is generally not necessary for the diagnosis of stasis dermatitis. However, in patients in whom the diagnosis is uncertain or who have atypical features (eg, solitary lesion, lack of ankle involvement), biopsy and histopathologic examination may confirm the diagnosis and/or exclude other skin diseases, such as allergic contact dermatitis, asteatotic eczema, or cutaneous malignancies (particularly in patients with a solitary lesion) [<a href="#rid26">26</a>]. (See <a class="local">'Pathology'</a> above.)</p><p>A skin biopsy should be made with caution or avoided in patients with concomitant peripheral arterial insufficiency, which is not uncommon. These patients have an increased risk of developing a nonhealing wound at the biopsy site due to insufficient blood supply. (See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a>.)</p><p class="headingAnchor" id="H106493086"><span class="h2">Additional evaluation</span></p><p class="headingAnchor" id="H3589094849"><span class="h3">Vascular studies</span><span class="headingEndMark"> — </span>Color Doppler assessment of the blood flow in the lower limbs is helpful in evaluating venous incompetence and/or diagnosing deep venous thrombosis in patients with skin findings but without obvious manifestations of venous insufficiency. Arterial study may be necessary to evaluate arterial disease in patients with trophic changes (eg, atrophie blanche or ulcerations). (See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a> and  <a class="medical medical_review" href="/z/d/html/8196.html" rel="external">"Diagnostic evaluation of lower extremity chronic venous disease", section on 'Venous duplex ultrasound'</a>.)</p><p class="headingAnchor" id="H3981937694"><span class="h3">Patch testing</span><span class="headingEndMark"> — </span>Patch testing for contact sensitization may be warranted for patients who experience a worsening of symptoms despite appropriate skin care and topical therapy. Standard series of allergens should be used in addition to other series selected on the basis of exposure history and clinical suspicion (eg, corticosteroids, rubber, preservatives, excipients, antioxidants, fragrances, textiles, and topical medicines or products used by the patient). The specific standard series may vary depending upon the location of the patch testing center [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a> and  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis"</a>.)</p><p class="headingAnchor" id="H108539"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Many common and uncommon skin disorders may mimic stasis dermatitis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common conditions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cellulitis – Lower limb cellulitis develops as a result of bacterial entry via breaches in the skin barrier. Cellulitis is typically unilateral; has an acute onset of symptoms (eg, erythema, edema, warmth); and is often accompanied by lymphangitis, pain, fever, and other systemic signs of infection  (<a class="graphic graphic_picture graphicRef82542" href="/z/d/graphic/82542.html" rel="external">picture 5</a> and <a class="graphic graphic_figure graphicRef139796" href="/z/d/graphic/139796.html" rel="external">figure 2</a>). Of note, cellulitis and erysipelas may be a complication of stasis dermatitis. (See <a class="local">'Superinfection'</a> above and  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Irritant or allergic contact dermatitis  (<a class="graphic graphic_picture graphicRef51220" href="/z/d/graphic/51220.html" rel="external">picture 6</a>). (See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asteatotic eczema (eczema craquelé)  (<a class="graphic graphic_picture graphicRef63945" href="/z/d/graphic/63945.html" rel="external">picture 7</a>). (See  <a class="medical medical_review" href="/z/d/html/1727.html" rel="external">"Overview of dermatitis (eczematous dermatoses)", section on 'Asteatotic eczema'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lichen simplex chronicus  (<a class="graphic graphic_picture graphicRef73843" href="/z/d/graphic/73843.html" rel="external">picture 8</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Psoriasis  (<a class="graphic graphic_picture graphicRef77308" href="/z/d/graphic/77308.html" rel="external">picture 9</a>). (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Chronic plaque psoriasis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dermatophyte infection (tinea corporis)  (<a class="graphic graphic_picture graphicRef53823" href="/z/d/graphic/53823.html" rel="external">picture 10</a>), which may also be a complication of stasis dermatitis. (See <a class="local">'Superinfection'</a> above and  <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Tinea corporis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Actinically damaged skin (multiple actinic keratoses). (See  <a class="medical medical_review" href="/z/d/html/13712.html" rel="external">"Actinic keratosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less common conditions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pigmented purpuric dermatoses – Pigmented purpuric dermatoses are a group of chronic, purpuric skin eruptions affecting the lower extremities in most cases and characterized by petechiae, red to purple macules and patches, and hyperpigmentation due to hemosiderin deposition  (<a class="graphic graphic_picture graphicRef76569 graphicRef88991" href="/z/d/graphic/76569.html" rel="external">picture 11A-B</a>). Pigmented purpuric dermatoses may be associated with chronic venous insufficiency [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/z/d/html/13757.html" rel="external">"Pigmented purpuric dermatoses (capillaritis)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertrophic lichen planus  (<a class="graphic graphic_picture graphicRef54396 graphicRef81589" href="/z/d/graphic/54396.html" rel="external">picture 12A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Necrobiosis lipoidica  (<a class="graphic graphic_picture graphicRef50781 graphicRef63574" href="/z/d/graphic/50781.html" rel="external">picture 13A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/89276.html" rel="external">"Necrobiosis lipoidica"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pretibial myxedema  (<a class="graphic graphic_picture graphicRef64524" href="/z/d/graphic/64524.html" rel="external">picture 14</a>). (See  <a class="medical medical_review" href="/z/d/html/7826.html" rel="external">"Pretibial myxedema (thyroid dermopathy) in autoimmune thyroid disease", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin cancer (squamous cell carcinoma, basal cell carcinoma). (See  <a class="medical medical_review" href="/z/d/html/16225.html" rel="external">"Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">"Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Clinical presentation'</a>.) </p><p></p><p class="headingAnchor" id="H26659847"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Our approach to the management of stasis dermatitis is illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef141440" href="/z/d/graphic/141440.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1700583262"><span class="h2">General measures</span></p><p class="headingAnchor" id="H957690579"><span class="h3">Lifestyle modifications</span><span class="headingEndMark"> — </span>Patients with chronic venous disease and stasis dermatitis should undertake lifestyle changes aimed at decreasing venous hypertension, reducing edema, and preventing venous ulcers. These include exercise, frequent walks, avoiding prolonged standing, leg elevation whenever possible, and weight loss.</p><p class="headingAnchor" id="H3749987667"><span class="h3">Skin care</span><span class="headingEndMark"> — </span>Gentle skin cleansing with mild, fragrance-free liquid cleansers and frequent use of bland emollients are indicated for the symptomatic treatment of skin dryness and pruritus associated with mild or chronic stasis dermatitis. Emollients provide a film of oil to lubricate the skin, which limits dryness and itching. Petrolatum-based products are preferred to emollients containing <a class="drug drug_general" data-topicid="101844" href="/z/d/drug information/101844.html" rel="external">lanolin</a> or fragrances to reduce the risk of contact sensitization. White petroleum jelly is effective, inexpensive, and nonsensitizing. Emollients can be applied multiple times per day. Emollients are best applied when the skin is damp (ie, immediately after showering or bathing) and may be applied after wet dressings to seal in hydration.</p><p class="headingAnchor" id="H3681452358"><span class="h2">Compression therapy</span><span class="headingEndMark"> — </span>Compression therapy, either with compression bandaging systems or compression stockings, is the mainstay of conservative treatment for stasis dermatitis and the underlying chronic venous disease  (<a class="graphic graphic_algorithm graphicRef141440" href="/z/d/graphic/141440.html" rel="external">algorithm 1</a>) [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compression bandages</strong> – Compression bandages, such as multilayer compression bandages and Unna boots, are preferred to compression stockings for patients with acute stasis dermatitis. The <a class="drug drug_general" data-topicid="10056" href="/z/d/drug information/10056.html" rel="external">Unna boot</a> is a closed topical dressing consisting of a moist, zinc oxide-impregnated bandage that provides nonelastic compression and topical treatment and has drying and anti-inflammatory properties. Both types of compression bandages should be applied by trained health care personnel and changed by them once or twice a week. (See  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency", section on 'Multilayer compression bandages'</a> and  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency", section on 'Unna boot'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compression stockings </strong>– Compression stockings are an alternative to compression bandages for patients with milder or chronic dermatitis. However, patients' adherence to the regular use of compression stockings is generally low due to multiple factors, including difficulty in donning, discomfort, overheating, itching, irritation, and financial concerns [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency", section on 'Compression hosiery'</a>.)</p><p></p><p class="headingAnchor" id="H2264954749"><span class="h2">Acute disease</span></p><p class="headingAnchor" id="H1340732932"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>We suggest topical corticosteroids for patients with stasis dermatitis who have erythema, pruritus, vesiculation, and oozing  (<a class="graphic graphic_algorithm graphicRef141440" href="/z/d/graphic/141440.html" rel="external">algorithm 1</a>). High- or mid-potency corticosteroids (groups 3 and 4  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)) in an ointment formulation can be applied to the affected skin once or twice daily for one to two weeks. A prolonged use of high-potency corticosteroids should be avoided since they may induce skin atrophy and increase the risk of ulceration.</p><p>Corticosteroid preparations containing emulsifiers and additives should be avoided to minimize the risk of sensitization. Petrolatum-based topical corticosteroids (eg, <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> ointment, <a class="drug drug_general" data-topicid="8458" href="/z/d/drug information/8458.html" rel="external">fluocinolone</a> ointment) are preferred because they do not contain any additives. Nonetheless, contact sensitization to topical corticosteroids may occur; a list of cross-reacting topical corticosteroids is provided in the figure  (<a class="graphic graphic_figure graphicRef63402" href="/z/d/graphic/63402.html" rel="external">figure 1</a>).</p><p>There are few low-quality studies evaluating topical corticosteroids for the treatment of stasis dermatitis [<a href="#rid32">32,33</a>]. In a small trial, patients treated with <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> valerate foam 0.12% or placebo twice daily for 28 days had similar improvement of edema, postinflammatory hyperpigmentation, or pruritus [<a href="#rid32">32</a>]. However, patients in the betamethasone group had greater improvement compared with baseline than those in the placebo group. It is not known whether stronger potency corticosteroids or an ointment preparation (rather than foam) would be more beneficial.</p><p class="headingAnchor" id="H26659861"><span class="h3">Wet dressings</span><span class="headingEndMark"> — </span>For patients with exudative eczema, wet dressings may facilitate the removal of crusts and exudate and reduce pruritus. Wet dressings are applied using tap water, <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, or an appropriate anti-infective solution diluted from stock (eg, zinc and copper sulfate solution, acetic acid, potassium permanganate, or <a class="drug drug_general" data-topicid="95641" href="/z/d/drug information/95641.html" rel="external">aluminum acetate</a> [Burow solution] or subacetate).</p><p>Saturated, but not dripping, soft cotton dermatologic roll gauze or cloths are applied directly to affected areas and covered with dry cotton, which is light and air permeable. The wet dressing is left in place for two to three hours and may be applied two to three times daily or continuously in more severe cases and in motivated patients. Emollients may be applied after removal to moisturize and seal in attained hydration.</p><p>Wet dressings may be used in conjunction with topical corticosteroids. The addition of dermatologic wet dressings to topical corticosteroids may increase the penetration and absorption of the corticosteroids.</p><p>In patients with bacterial superinfection, antibacterial wet dressings may help clear secondary impetiginization and obviate the need for topical or oral antibiotic therapy.</p><p class="headingAnchor" id="H3288133553"><span class="h3">Response assessment</span><span class="headingEndMark"> — </span>In the absence of complications (eg, infection, contact sensitization), improvement is expected to occur in a few days of starting treatment. We typically re-evaluate patients at intervals of one to two weeks, depending on disease severity.</p><p class="headingAnchor" id="H523344201"><span class="h3">Recalcitrant disease</span><span class="headingEndMark"> — </span>Patients with persisting or worsening symptoms despite appropriate initial therapy should be evaluated for concomitant allergic contact dermatitis or superimposed infection  (<a class="graphic graphic_algorithm graphicRef141440" href="/z/d/graphic/141440.html" rel="external">algorithm 1</a>). Referral to a vein specialist may be indicated for patients with unsatisfactory responses to initial therapy.</p><p class="headingAnchor" id="H2508546009"><span class="h4">Assess and treat allergic contact dermatitis</span><span class="headingEndMark"> — </span>Patients in whom stasis dermatitis does not improve or worsens after an adequate course of topical therapy should be evaluated for allergic contact dermatitis. (See <a class="local">'Contact sensitization'</a> above and <a class="local">'Patch testing'</a> above.)</p><p>For patients with confirmed concurrent allergic contact dermatitis, we suggest a short course of systemic corticosteroids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 to 40 mg daily for five to seven days). An alternative is a single dose of intramuscular <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 40 mg.</p><p>Substitution with alternative topical and contact therapies is recommended. Strict allergen avoidance measures should be utilized when patch testing is not possible due to logistic or availability reasons.</p><p>Data on the efficacy of systemic corticosteroids for the treatment of recalcitrant stasis dermatitis are lacking. Their use is based upon indirect evidence of efficacy in severe allergic contact dermatitis and clinical experience. (See  <a class="medical medical_review" href="/z/d/html/13665.html" rel="external">"Management of allergic contact dermatitis in adults"</a>.)</p><p class="headingAnchor" id="H3645062208"><span class="h4">Assess and treat secondary infection</span><span class="headingEndMark"> — </span>Bacterial cultures and/or mycologic studies (eg, potassium hydroxide [KOH] preparation) may be useful when bacterial or fungal superinfection is suspected. (See  <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superficial infection</strong> – We suggest topical antibiotic therapy for patients with stasis dermatitis and impetiginized lesions. Topical antibacterial ointments should be selected based upon the results of bacterial culture, if available, and risk of contact sensitization. <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">Mupirocin</a> is the topical antibiotic of choice for impetiginization of stasis dermatitis when <em>Staphylococcus</em> or <em>Streptococcus</em> is documented and as empirical starting treatment pending culture results or in cases in which culture is not available, as it is unlikely to cause cutaneous sensitization [<a href="#rid34">34,35</a>]. Topical <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> ointment is an alternative treatment when mupirocin is not tolerated [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo", section on 'Topical therapy'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">Bacitracin</a>, <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a>, and aminoglycosides should be avoided, as they frequently induce contact sensitization in patients with stasis dermatitis [<a href="#rid13">13</a>]. Triclosan-based topical antimicrobial preparations are an infrequent cause of contact sensitization and may be used as an alternative to topical antibiotics. The topical use of triclosan has been restricted in the United States since December 2017 [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">Direct <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> scrubs in the shower or diluted bleach baths (one-half cup in a bathtub half full of tepid water) are also useful to decrease the cutaneous bacterial load. Topical antibacterial wet dressings utilizing 1% glacial acetic acid solution or a white vinegar 1:8 dilution may also assist in decreasing surface bacterial content and removing crusted impetiginization [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellulitis</strong> – For patients with clinical signs of cellulitis, such as acute worsening of erythema and edema (especially if unilateral), pain, and fever  (<a class="graphic graphic_figure graphicRef139796" href="/z/d/graphic/139796.html" rel="external">figure 2</a>), we suggest systemic antibiotics. Pending culture results, empiric therapy covering group B <em>Streptococcus</em>, methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), and other beta-hemolytic streptococci can be initiated. The choice of oral or parenteral antibiotics is based on the presence and severity of systemic and local symptoms  (<a class="graphic graphic_algorithm graphicRef139109" href="/z/d/graphic/139109.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H1757399532"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>Patients with stasis dermatitis that does not improve with compression therapy and optimal topical therapy (after exclusion of secondary contact dermatitis or infection) should be referred to a vascular specialist for further evaluation and treatment. Infection disease consultation is warranted for patients with atypical or severe infection.</p><p class="headingAnchor" id="H376054185"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118466.html" rel="external">"Society guideline links: Chronic venous disorders"</a>.)</p><p class="headingAnchor" id="H714779274"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15729.html" rel="external">"Patient education: Varicose veins and other vein disease in the legs (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26659945"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Stasis dermatitis, or stasis eczema, is a common, inflammatory dermatosis of the lower legs caused by venous hypertension, which results from dysfunction of the venous valves, obstruction to the venous flow, and failure of the "venous pump." Venous hypertension induces changes in the dermis, including dilated capillaries with fibrin cuffs, deposition of hemosiderin, and accumulation of macrophages and other inflammatory cells, resulting in chronic inflammation and changes in the overlying skin. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Signs and symptoms of stasis dermatitis include edema, inflammatory and trophic skin changes, pruritus, and hyperpigmentation. Manifestations of more advanced venous disease include lipodermatosclerosis  (<a class="graphic graphic_picture graphicRef65447" href="/z/d/graphic/65447.html" rel="external">picture 3</a>), lymphedema, and ulceration. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Contact sensitization and secondary infection are common complications of stasis dermatitis. Contact sensitization should be suspected in patients with atypical presentations and in patients failing to respond to appropriate treatment for stasis dermatitis. (See <a class="local">'Contact sensitization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of stasis dermatitis is based upon the clinical appearance of the skin lesions (ranging from erythema, scaling, and hyperpigmentation to edema, erosions, and crusts)  (<a class="graphic graphic_picture graphicRef70596 graphicRef50640 graphicRef56758" href="/z/d/graphic/70596.html" rel="external">picture 1A, 1C, 1F</a>); history of venous insufficiency; and other clinical signs of chronic venous insufficiency, including varicosities, pitting edema, and hyperpigmentation  (<a class="graphic graphic_figure graphicRef139796" href="/z/d/graphic/139796.html" rel="external">figure 2</a>). In patients with atypical presentations or solitary lesions, biopsy and histopathologic examination may confirm the diagnosis and/or exclude other dermatoses or skin cancer. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong>  (<a class="graphic graphic_algorithm graphicRef141440" href="/z/d/graphic/141440.html" rel="external">algorithm 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Compression therapy</strong> – Compression therapy, either with compression bandaging systems or compression stockings, is the first-line, conservative treatment for stasis dermatitis and the underlying chronic venous disease. Compression bandages and Unna boots applied by trained health care personnel are beneficial for patients with acute, severe disease in conjunction with topical therapies. (See  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute disease</strong> – For patients with stasis dermatitis who have erythema, pruritus, vesiculation, and oozing, we suggest topical corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). High- or mid-potency corticosteroids (groups 3 and 4  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)) in an ointment formulation may be applied once or twice daily for one to two weeks to the affected skin. Wet dressings may be used in conjunction with topical corticosteroids in patients with exudative eczema and crusting. Emollients with low sensitizing potential (eg, petroleum jelly) can be used multiple times per day to improve skin dryness and pruritus. (See <a class="local">'Topical corticosteroids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recalcitrant disease</strong> – Patients with persisting or worsening symptoms despite appropriate initial therapy should be evaluated for concomitant allergic contact dermatitis or superimposed infection. (See <a class="local">'Recalcitrant disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients with concurrent allergic contact dermatitis</strong> – For patients with confirmed concurrent allergic contact dermatitis, we suggest a short course of systemic corticosteroids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 20 to 30 mg daily for five to seven days) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Assess and treat allergic contact dermatitis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients with secondary infection</strong> – For patients with superficial superinfection (impetiginization), we suggest topical <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a>, as it is unlikely to cause cutaneous sensitization (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Assess and treat secondary infection'</a> above and  <a class="medical medical_review" href="/z/d/html/7655.html" rel="external">"Impetigo", section on 'Topical therapy'</a>.)</p><p></p><p class="bulletIndent3">For patients with clinical signs of cellulitis (eg, acute worsening of erythema and edema, pain, and fever  (<a class="graphic graphic_figure graphicRef139796" href="/z/d/graphic/139796.html" rel="external">figure 2</a>)), systemic antibiotics are administered. Pending culture results, empiric therapy should cover group B<em> Streptococcus</em>, methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), and other beta-hemolytic streptococci. (See  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for referral</strong> – Referral to a vascular specialist is indicated for patients with stasis dermatitis that does not respond to appropriate dermatologic therapy and compression. Infection disease consultation is warranted for patients with atypical or severe infection. (See <a class="local">'Indications for referral'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Deguchi E, Imafuku S, Nakayama J. Ulcerating stasis dermatitis of the forearm due to arteriovenous fistula: a case report and review of the published work. J Dermatol 2010; 37:550.</a></li><li><a class="nounderline abstract_t">Sundaresan S, Migden MR, Silapunt S. Stasis Dermatitis: Pathophysiology, Evaluation, and Management. Am J Clin Dermatol 2017; 18:383.</a></li><li><a class="nounderline abstract_t">Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 2005; 15:175.</a></li><li><a class="nounderline abstract_t">Yalçin B, Tamer E, Toy GG, et al. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. Int J Dermatol 2006; 45:672.</a></li><li><a class="nounderline abstract_t">Fiebig A, Krusche P, Wolf A, et al. Heritability of chronic venous disease. Hum Genet 2010; 127:669.</a></li><li><a class="nounderline abstract_t">Bergan JJ, Schmid-Schönbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med 2006; 355:488.</a></li><li><a class="nounderline abstract_t">Silverberg J, Jackson JM, Kirsner RS, et al. Narrative Review of the Pathogenesis of Stasis Dermatitis: An Inflammatory Skin Manifestation of Venous Hypertension. Dermatol Ther (Heidelb) 2023; 13:935.</a></li><li><a class="nounderline abstract_t">Herouy Y, Mellios P, Bandemir E, et al. Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression. J Dermatol Sci 2001; 25:198.</a></li><li><a class="nounderline abstract_t">Alsaigh T, Pocock ES, Bergan JJ, Schmid-Schönbein GW. Acute venous occlusion enhances matrix metalloprotease activity: Implications on endothelial dysfunction. Microvasc Res 2011; 81:108.</a></li><li><a class="nounderline abstract_t">Eklöf B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40:1248.</a></li><li class="breakAll">Stasis dermatitis. In: Weedon's Skin Pathology, 3rd ed, Weedon D (Ed), Churchill Livingstone Elsevier, 2010.</li><li><a class="nounderline abstract_t">Northcutt AD, Tschen JA. The routine use of iron stain for biopsies of dermatoses of the legs. J Cutan Pathol 2015; 42:717.</a></li><li><a class="nounderline abstract_t">Silverberg JI, Hou A, Warshaw EM, et al. Prevalence and trend of allergen sensitization in patients with a diagnosis of stasis dermatitis referred for patch testing, North American contact dermatitis group data, 2001-2016. Arch Dermatol Res 2022; 314:857.</a></li><li><a class="nounderline abstract_t">Barbaud A, Collet E, Le Coz CJ, et al. Contact allergy in chronic leg ulcers: results of a multicentre study carried out in 423 patients and proposal for an updated series of patch tests. Contact Dermatitis 2009; 60:279.</a></li><li><a class="nounderline abstract_t">Bahmer FA, Lesch H. Density of Langerhans' cells in ATPase stained epidermal sheet preparations from stasis dermatitis skin of the lower leg. Acta Derm Venereol 1987; 67:301.</a></li><li><a class="nounderline abstract_t">Scott HJ, Coleridge Smith PD, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. Br J Surg 1991; 78:210.</a></li><li><a class="nounderline abstract_t">Prakash AV, Davis MD. Contact dermatitis in older adults: a review of the literature. Am J Clin Dermatol 2010; 11:373.</a></li><li class="breakAll">Belsito DV. Autosensitization dermatitis. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill Medical, 2008. Vol I, p.167.</li><li><a class="nounderline abstract_t">Bendl BJ. Nummular eczema of statis origin. The backbone of a morphologic pattern of diverse etiology. Int J Dermatol 1979; 18:129.</a></li><li><a class="nounderline abstract_t">HAXTHAUSEN H. Generalized ids autosensitization in varicose eczemas. Acta Derm Venereol 1955; 35:271.</a></li><li><a class="nounderline abstract_t">Hirschmann JV, Raugi GJ. Lower limb cellulitis and its mimics: part II. Conditions that simulate lower limb cellulitis. J Am Acad Dermatol 2012; 67:177.e1.</a></li><li><a class="nounderline abstract_t">Walsh SN, Santa Cruz DJ. Lipodermatosclerosis: a clinicopathological study of 25 cases. J Am Acad Dermatol 2010; 62:1005.</a></li><li><a class="nounderline abstract_t">Huang TM, Lee JY. Lipodermatosclerosis: a clinicopathologic study of 17 cases and differential diagnosis from erythema nodosum. J Cutan Pathol 2009; 36:453.</a></li><li><a class="nounderline abstract_t">Mehta AA, Pereira RR, Nayak CS, Dhurat RS. Acroangiodermatitis of mali: a rare vascular phenomenon. Indian J Dermatol Venereol Leprol 2010; 76:553.</a></li><li><a class="nounderline abstract_t">Lugović L, Pusić J, Situm M, et al. Acroangiodermatitis (pseudo-Kaposi sarcoma): three case reports. Acta Dermatovenerol Croat 2007; 15:152.</a></li><li><a class="nounderline abstract_t">Weaver J, Billings SD. Initial presentation of stasis dermatitis mimicking solitary lesions: a previously unrecognized clinical scenario. J Am Acad Dermatol 2009; 61:1028.</a></li><li class="breakAll">DermNet. Baseline series of patch test allergens. www.dermnetnz.org/dermatitis/standard-patch.html (Accessed on July 27, 2011).</li><li><a class="nounderline abstract_t">Parsi K, Kim B, O'Connor AA, et al. Chronic venous disease, platelet and haemostatic abnormalities contribute to the pathogenesis of pigmented purpuric dermatoses. Phlebology 2022; 37:348.</a></li><li><a class="nounderline abstract_t">Kim HJ, Lee GW, Son JW, et al. Venous Insufficiency is a Clear Provoker of Pigmented Purpuric Dermatosis. Ann Dermatol 2022; 34:34.</a></li><li><a class="nounderline abstract_t">De Maeseneer MG, Kakkos SK, Aherne T, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg 2022; 63:184.</a></li><li><a class="nounderline abstract_t">Coral FE, Guarinello GG, Cavassola AP, et al. Chronic venous insufficiency and graduated compression stockings: analysis of public health system patients' adherence to treatment. J Vasc Bras 2021; 20:e20200034.</a></li><li><a class="nounderline abstract_t">Weiss SC, Nguyen J, Chon S, Kimball AB. A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis. J Drugs Dermatol 2005; 4:339.</a></li><li><a class="nounderline abstract_t">Henry M, Hanks G, Whelan A. A randomized, double-blind therapeutic trial of 0.25% desoxymethasone and 0.1% hydrocortisone 17-butyrate in the treatment of varicose eczema. Curr Med Res Opin 1980; 6:502.</a></li><li><a class="nounderline abstract_t">Tomljanović-Veselski M, Lipozencić J, Lugović L. Contact allergy to special and standard allergens in patients with venous ulcers. Coll Antropol 2007; 31:751.</a></li><li><a class="nounderline abstract_t">Jindal R, Sharma NL, Mahajan VK, Tegta GR. Contact sensitization in venous eczema: preliminary results of patch testing with Indian standard series and topical medicaments. Indian J Dermatol Venereol Leprol 2009; 75:136.</a></li><li><a class="nounderline abstract_t">Bernstein SC, Roenigk RK. Surgical pearl: erythromycin ointment for topical antibiotic wound care. J Am Acad Dermatol 1995; 32:659.</a></li><li><a class="nounderline abstract_t">Schena D, Papagrigoraki A, Girolomoni G. Sensitizing potential of triclosan and triclosan-based skin care products in patients with chronic eczema. Dermatol Ther 2008; 21 Suppl 2:S35.</a></li><li><a class="nounderline abstract_t">Agrawal KS, Sarda AV, Shrotriya R, et al. Acetic acid dressings: Finding the Holy Grail for infected wound management. Indian J Plast Surg 2017; 50:273.</a></li></ol></div><div id="topicVersionRevision">Topic 13670 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536671" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ulcerating stasis dermatitis of the forearm due to arteriovenous fistula: a case report and review of the published work.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063094" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Stasis Dermatitis: Pathophysiology, Evaluation, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15723761" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The epidemiology of chronic venous insufficiency and varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16796625" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20354728" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Heritability of chronic venous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885552" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chronic venous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36949275" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Narrative Review of the Pathogenesis of Stasis Dermatitis: An Inflammatory Skin Manifestation of Venous Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11240267" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923679" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute venous occlusion enhances matrix metalloprotease activity: Implications on endothelial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622385" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Revision of the CEAP classification for chronic venous disorders: consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622385" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Revision of the CEAP classification for chronic venous disorders: consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24517257" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The routine use of iron stain for biopsies of dermatoses of the legs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34748058" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence and trend of allergen sensitization in patients with a diagnosis of stasis dermatitis referred for patch testing, North American contact dermatitis group data, 2001-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397620" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Contact allergy in chronic leg ulcers: results of a multicentre study carried out in 423 patients and proposal for an updated series of patch tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2445147" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Density of Langerhans' cells in ATPase stained epidermal sheet preparations from stasis dermatitis skin of the lower leg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2015476" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20812765" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Contact dermatitis in older adults: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20812765" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Contact dermatitis in older adults: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/422311" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nummular eczema of statis origin. The backbone of a morphologic pattern of diverse etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13301304" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Generalized ids autosensitization in varicose eczemas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22794816" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Lower limb cellulitis and its mimics: part II. Conditions that simulate lower limb cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466175" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lipodermatosclerosis: a clinicopathological study of 25 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19278432" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lipodermatosclerosis: a clinicopathologic study of 17 cases and differential diagnosis from erythema nodosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826998" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acroangiodermatitis of mali: a rare vascular phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868541" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Acroangiodermatitis (pseudo-Kaposi sarcoma): three case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19925928" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Initial presentation of stasis dermatitis mimicking solitary lesions: a previously unrecognized clinical scenario.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19925928" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Initial presentation of stasis dermatitis mimicking solitary lesions: a previously unrecognized clinical scenario.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35319303" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Chronic venous disease, platelet and haemostatic abnormalities contribute to the pathogenesis of pigmented purpuric dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35221593" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Venous Insufficiency is a Clear Provoker of Pigmented Purpuric Dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35027279" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34163533" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chronic venous insufficiency and graduated compression stockings: analysis of public health system patients' adherence to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15898290" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6988176" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A randomized, double-blind therapeutic trial of 0.25% desoxymethasone and 0.1% hydrocortisone 17-butyrate in the treatment of varicose eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18041384" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Contact allergy to special and standard allergens in patients with venous ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293499" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Contact sensitization in venous eczema: preliminary results of patch testing with Indian standard series and topical medicaments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7896958" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Surgical pearl: erythromycin ointment for topical antibiotic wound care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18837732" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sensitizing potential of triclosan and triclosan-based skin care products in patients with chronic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29618862" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Acetic acid dressings: Finding the Holy Grail for infected wound management.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
